372 related articles for article (PubMed ID: 27708221)
1. PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma.
Yang H; Zhao X; Zhao L; Liu L; Li J; Jia W; Liu J; Huang G
Oncotarget; 2016 Nov; 7(44):72131-72147. PubMed ID: 27708221
[TBL] [Abstract][Full Text] [Related]
2. Cyclin Y binds and activates CDK4 to promote the G1/S phase transition in hepatocellular carcinoma cells via Rb signaling.
Chen L; Wang X; Cheng H; Zhang W; Liu Y; Zeng W; Yu L; Huang C; Liu G
Biochem Biophys Res Commun; 2020 Dec; 533(4):1162-1169. PubMed ID: 33039146
[TBL] [Abstract][Full Text] [Related]
3. Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin.
Zhang B; Dong S; Li Z; Lu L; Zhang S; Chen X; Cen X; Wu Y
J Transl Med; 2015 Nov; 13():349. PubMed ID: 26541651
[TBL] [Abstract][Full Text] [Related]
4. PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27
Tuo L; Xiang J; Pan X; Hu J; Tang H; Liang L; Xia J; Hu Y; Zhang W; Huang A; Wang K; Tang N
J Exp Clin Cancer Res; 2019 Feb; 38(1):50. PubMed ID: 30717766
[TBL] [Abstract][Full Text] [Related]
5. PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma.
Jiang H; Zhu Y; Zhou Z; Xu J; Jin S; Xu K; Zhang H; Sun Q; Wang J; Xu J
Cancer Med; 2018 Mar; 7(3):869-882. PubMed ID: 29441724
[TBL] [Abstract][Full Text] [Related]
6. Notch1 is a potential therapeutic target for the treatment of human hepatitis B virus X protein-associated hepatocellular carcinoma.
Sun Q; Wang R; Wang Y; Luo J; Wang P; Cheng B
Oncol Rep; 2014 Feb; 31(2):933-9. PubMed ID: 24336972
[TBL] [Abstract][Full Text] [Related]
7. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
[TBL] [Abstract][Full Text] [Related]
8. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
Rivadeneira DB; Mayhew CN; Thangavel C; Sotillo E; Reed CA; Graña X; Knudsen ES
Gastroenterology; 2010 May; 138(5):1920-30. PubMed ID: 20100483
[TBL] [Abstract][Full Text] [Related]
9. Metadherin-PRMT5 complex enhances the metastasis of hepatocellular carcinoma through the WNT-β-catenin signaling pathway.
Zhu K; Peng Y; Hu J; Zhan H; Yang L; Gao Q; Jia H; Luo R; Dai Z; Tang Z; Fan J; Zhou J
Carcinogenesis; 2020 Apr; 41(2):130-138. PubMed ID: 31498866
[TBL] [Abstract][Full Text] [Related]
10. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
[TBL] [Abstract][Full Text] [Related]
11. Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells.
Jeon JY; Lee JS; Park ER; Shen YN; Kim MY; Shin HJ; Joo HY; Cho EH; Moon SM; Shin US; Park SH; Han CJ; Choi DW; Gu MB; Kim SB; Lee KH
Oncol Rep; 2018 Jul; 40(1):536-544. PubMed ID: 29749478
[TBL] [Abstract][Full Text] [Related]
12. Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth.
Wang Z; Wei W; Sun CK; Chua MS; So S
Liver Int; 2015 Apr; 35(4):1403-15. PubMed ID: 25098386
[TBL] [Abstract][Full Text] [Related]
13. Oncogene RPA1 promotes proliferation of hepatocellular carcinoma via CDK4/Cyclin-D pathway.
Wang J; Yang T; Chen H; Li H; Zheng S
Biochem Biophys Res Commun; 2018 Apr; 498(3):424-430. PubMed ID: 29477843
[TBL] [Abstract][Full Text] [Related]
14. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
[TBL] [Abstract][Full Text] [Related]
15. Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
Luo Y; Gao Y; Liu W; Yang Y; Jiang J; Wang Y; Tang W; Yang S; Sun L; Cai J; Guo X; Takahashi S; Krausz KW; Qu A; Chen L; Xie C; Gonzalez FJ
Hepatology; 2021 Oct; 74(4):1932-1951. PubMed ID: 33896016
[TBL] [Abstract][Full Text] [Related]
16. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
17. Vitamins K2, K3 and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules.
Kuriyama S; Hitomi M; Yoshiji H; Nonomura T; Tsujimoto T; Mitoro A; Akahane T; Ogawa M; Nakai S; Deguchi A; Masaki T; Uchida N
Int J Oncol; 2005 Aug; 27(2):505-11. PubMed ID: 16010434
[TBL] [Abstract][Full Text] [Related]
18. The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy.
Shimizu D; Kanda M; Sugimoto H; Shibata M; Tanaka H; Takami H; Iwata N; Hayashi M; Tanaka C; Kobayashi D; Yamada S; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
Int J Oncol; 2017 Feb; 50(2):381-386. PubMed ID: 28101581
[TBL] [Abstract][Full Text] [Related]
19. The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro.
Tanaka S; Suzuki K; Sakaguchi M
Breast Cancer; 2017 Sep; 24(5):658-666. PubMed ID: 28070831
[TBL] [Abstract][Full Text] [Related]
20. RN181 is a tumour suppressor in gastric cancer by regulation of the ERK/MAPK-cyclin D1/CDK4 pathway.
Wang S; Wang X; Gao Y; Peng Y; Dong N; Xie Q; Zhang X; Wu Y; Li M; Li JL
J Pathol; 2019 Jun; 248(2):204-216. PubMed ID: 30714150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
